MXCT stock is currently trading at a significant discount, with its intrinsic value estimated to be 42% higher than its current price of £3.24, suggesting strong upside potential. The company's recent acquisition of SeQure Dx is expected to improve revenue and reduce losses, aligning with its strategy to enhance service offerings and operational efficiency. Additionally, MaxCyte's Q4 2024 core revenue growth of 15% year-over-year reflects positive momentum in the cell therapy industry, supporting a bullish outlook.